Besides Wall Street's top-and-bottom-line estimates for Kenvue (KVUE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.

J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart. In 2023, shareholders received new shares of Kenvue, which used to be the ...

Board director Kirk Perry has been named interim CEO while the company undergoes a strategic review aimed at simplifying its operations and strengthening performance after ... The post Kenvue stock ...

Meanwhile, broader market trends remained flat amid geopolitical uncertainties and cryptocurrency rallies, which added mixed sentiments to stock prices overall ... investor pressure to boost ...

Kenvue, which was spun off from Johnson & Johnson in 2023, has been working to shore up profitability, especially in its struggling skin health and beauty unit which includes brands like Neutrogena ...

Kenvue stock yo-yoes Monday after the company — known for brands like Tylenol — announced a new CEO and strategic review.

U.S. companies are removing their CEOs at the fastest clip in two decades, data shows, as increased scrutiny from ...

J&J’s shares have outperformed the industry year to date. The stock has risen 15.1% in the year-to-date period against a 0.5% ...

J&J has an Earnings ESP of +2.40% and a Zacks Rank #2 (Buy), indicating a likely positive surprise. Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 ...

Dividend stocks are thriving as rates drop. Explore Kiplinger's top picks for high returns, low risk, and steady growth.